Key statistics
On Friday, Immunitybio Inc (26CA:BER) closed at 3.44, 56.62% above the 52 week low of 2.20 set on Jan 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.19 |
---|---|
High | 3.65 |
Low | 3.14 |
Bid | 3.35 |
Offer | 3.55 |
Previous close | 3.19 |
Average volume | 4.48k |
---|---|
Shares outstanding | 730.16m |
Free float | 159.91m |
P/E (TTM) | -- |
Market cap | 2.45bn USD |
EPS (TTM) | -0.867 USD |
Data delayed at least 15 minutes, as of Feb 14 2025 20:40 GMT.
More ▼
Press releases
- ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
- ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
- ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
- ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
- ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
- ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
- ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
- ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
- ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
More ▼